\u003cb\u003eWritten and edited by global leaders\u003c/b\u003e in this challenging field, \u003ci\u003eRare and Interstitial Lung Diseases: Clinical Cases and Real-World Discussions\u003c/i\u003e brings you up to date with the latest advances in complex or rare lung diseases managed on outpatient or inpatient respiratory or critical care units. Using a \u003cb\u003eunique, case-based approach\u003c/b\u003e, a wide variety of cases are presented along with \u003cb\u003eperspectives from a multidisciplinary team of experts\u003c/b\u003e who discuss therapeutic choices and rationales. This real-world approach \u003cb\u003eallows the reader to become a virtual attending physician\u003c/b\u003e, simulating a realistic clinical reasoning process on the diagnosis, treatment, and follow-up of patients with rare and complex lung diseases.\u003cul\u003e\u003cli\u003eReflects a \u003cb\u003enuanced, multidisciplinary, evidence-based approach to diagnoses, treatment options, and follow-up\u003c/b\u003e criteria for complex and rare pulmonary disorders such as idiopathic pulmonary fibrosis, interstitial lung disease related to connective tissue diseases, hypersensitivity pneumonitis, sarcoidosis, and pulmonary vascular disease.\u003c/li\u003e\u003cli\u003e\u003cb\u003eEach case\u003c/b\u003e includes onset of symptoms, diagnostic/therapeutic path, and discussions on the clinical choices made in accordance with evidence-based medical procedures.\u003c/li\u003e\u003cli\u003eDescribes each clinical and laboratory finding and \u003cb\u003efeatures 150 images\u003c/b\u003e, including plain film, procedural photos, ultrasound images, CT scans, and histopathology specimens.\u003c/li\u003e\u003cli\u003eIncludes the most \u003cb\u003erecent updates to international guidelines\u003c/b\u003e (ATS/ERS/JRS/ALAT) on idiopathic pulmonary fibrosis (IPF).\u003c/li\u003e\u003cli\u003eCovers the progression of pulmonary fibrosis in patients with ILD other than IPF; the role of transbronchial lung cryobiopsy (TBLC) in obtaining a tissue diagnosis in patients with undiagnosed ILD; and the indications of antifibrosant drugs.\u003c/li\u003e\u003cli\u003eA \u003cb\u003epractical and interactive resource\u003c/b\u003e for pulmonologists, as well as critical care and internal medicine practitioners and fellows, thoracic surgeons, and thoracic radiologists.\u003c/li\u003e\u003c/ul\u003e\u003cul\u003e\u003cli\u003eAny additional digital ancillary content may publish up to 6 weeks following the publication date.\u003c/li\u003e\u003c/ul\u003e
nl
en